CN102861096B - Application of Houttuynoid E in preparing medicine for treating cervical cancer - Google Patents
Application of Houttuynoid E in preparing medicine for treating cervical cancer Download PDFInfo
- Publication number
- CN102861096B CN102861096B CN 201210418802 CN201210418802A CN102861096B CN 102861096 B CN102861096 B CN 102861096B CN 201210418802 CN201210418802 CN 201210418802 CN 201210418802 A CN201210418802 A CN 201210418802A CN 102861096 B CN102861096 B CN 102861096B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- cervical cancer
- application
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Houttuynoid E in preparation of a medicine for treating human cervical cancer, belonging to the technical field of new application of medicine. The invention discovers that Houttuynoid E has the remarkable inhibitory effects on the growth of human cervical cancer cell strains, including HeLa, HeLa229, HCE1 and CaSKi through the evaluation of in vitro MTT antineoplastic activity. Therefore, Houttuynoid E can be used for preparing the anti-cervical cancer medicine and has good development and application prospects. The application of Houttuynoid E in preparation of the medicine for treating human cervical cancer provided by the invention is disclosed firstly. The skeleton type belongs to new skeleton type, and the inhibitory activity of Houttuynoid E on human cervical cancer cells is unexpectedly strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid E, relate in particular to the application of Houttuynoid E in the preparation medicament for resisting cervical cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the reasonable antitumor drug of effect clinically at present as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound H outtuynoid E that the present invention relates to is one and delivered (Chen in 2012, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) new framework compound, this chemical compound has brand-new framework types, present purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), belong to open first for the purposes of the Houttuynoid E that the present invention relates in preparation treatment cervical cancer medicine, because framework types belongs to brand-new framework types, and its inhibition for cervical cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for cervical cancer simultaneously obviously has obvious improvement.
Summary of the invention
The invention provides the application of compound H outtuynoid E in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid E in the preparation medicament for resisting cervical cancer, and the structural formula of Houttuynoid E is shown in formula I:
The present invention finds that by external MTT anti-tumor activity evaluation the growth of the human cervical carcinoma cell strain of Houttuynoid E HeLa, HeLa229, HCE1 and CaSKi also has significant inhibitory effect, suppresses the IC of this 4 strain cell growth
50Value is respectively 0.83 ± 0.02 μ M, 1.13 ± 0.03 μ M, 0.52 ± 0.07 μ M and 0.97 ± 0.06 μ M.Therefore, Houttuynoid E can have the excellent development application prospect for the preparation of medicament for resisting cervical cancer.
The purposes of the Houttuynoid E that the present invention relates in preparation treatment cervical cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for cervical cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for cervical cancer simultaneously obviously has obvious improvement.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid E involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid E_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound H outtuynoid E tablet involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound H outtuynoid E capsule involved in the present invention:
Get 20 and digest compound Houttuynoid E, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt the growth inhibited effect of the human cervical carcinoma cell strain of mtt assay assessing compound Houttuynoid E
1. method: the cell that is in the growth logarithmic (log) phase: human cervical carcinoma cell strain HeLa, HeLa229, HCE1 and CaSKi(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Cell culture 24 h inhale adherent back and go original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid E of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, inhale along culture fluid top then and remove 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: the growth of the human cervical carcinoma cell strain of Houttuynoid E HeLa, HeLa229, HCE1 and CaSKi has significant inhibitory effect.This chemical compound suppresses the IC of human cervical carcinoma cell strain HeLa, HeLa229, HCE1 and CaSKi growth
50Value is respectively: 0.83 ± 0.02 μ M, 1.13 ± 0.03 μ M, 0.52 ± 0.07 μ M and 0.97 ± 0.06 μ M.
Shown that by above-described embodiment the growth of the human cervical carcinoma cell strain of Houttuynoid E of the present invention HeLa, HeLa229, HCE1 and CaSKi has the good restraining effect.Prove that thus Houttuynoid E of the present invention has the anti-cervical cancer activity, can be for the preparation of medicament for resisting cervical cancer.
Claims (1)
1.Houttuynoid the application of E in preparation treatment cervical cancer medicine, described compound H outtuynoid E structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210418802 CN102861096B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in preparing medicine for treating cervical cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210418802 CN102861096B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in preparing medicine for treating cervical cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861096A CN102861096A (en) | 2013-01-09 |
| CN102861096B true CN102861096B (en) | 2013-07-17 |
Family
ID=47440414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210418802 Expired - Fee Related CN102861096B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid E in preparing medicine for treating cervical cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861096B (en) |
-
2012
- 2012-10-27 CN CN 201210418802 patent/CN102861096B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| Houttuynoids A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen等;《Organic Letters》;20120313;第14卷(第7期);1772-1775 * |
| Shao-DanChen等.HouttuynoidsA-E Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《Organic Letters》.2012 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861096A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861065B (en) | Application of Houttuynoid E in medicine for treating gastric cancer | |
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102861064B (en) | Application of Houttuynoid E in preparing medicine for treating laryngocarcinoma | |
| CN102861069B (en) | Application of Houttuynoid B in medicine for treating laryngocarcinoma | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102861089B (en) | Application of Houttuynoid B in medicine for treating liver cancer | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102872077B (en) | Application of Houttuynoid B in drugs for treating endometrial cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102872093B (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102861058B (en) | Application of Houttuynoid D in cholangiocarcinoma treatment medicine | |
| CN102861097B (en) | Application of Houttuynoid E in medicine for treating bladder cancer | |
| CN102861084B (en) | Application of Houttuynoid D in medicine for treating ileocecum cancer | |
| CN102861056B (en) | Application of Houttuynoid A in endometrial cancer treatment medicine | |
| CN102861057B (en) | Application of Houttuynoid D in skin cancer treatment medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: A. V. T. (LIYANG) MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WU JUNHUA Effective date: 20131209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 213351 CHANGZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131209 Address after: 213351 Wuhu Road, Liyang Economic Development Zone, Changzhou, Jiangsu 168, Liyang Patentee after: A.V.T.(Liyang) Medical Science & Technology Co., Ltd. Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130717 Termination date: 20151027 |
|
| EXPY | Termination of patent right or utility model |